Dealing with the Verteporfin Shortage: Treatment Options and Outcomes in Patients with Chronic and Non-Resolving Central Serous Chorioretinopathy
Ophthalmologica · 24.10.2024 · 1-11
DOI: 10.1159/000542224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmologica, online erschienen am 24.10.2024. Verfasst von Femke M van den Tillaart und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands, femke.vandentillaart@radboudumc.nl. Hauptthemen laut MEDLINE: Verteporfin, Central Serous Chorioretinopathy, Photochemotherapy, Visual Acuity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Half-dose photodynamic therapy (HD-PDT) with verteporfin is the mainstay treatment in central serous chorioretinopathy (CSC). Since 2021, there is a worldwide shortage of verteporfin. This called for adjustments of daily practice. Here, we provide a comprehensive evaluation of the adapted treatment methods and outcomes in patients with non-resolving and chronic CSC.
Methods
In this retrospective cohort study, we compared patients referred in the year before the verteporfin shortage (group 1), with patients referred in the first year of verteporfin shortage (group 2). Treatment strategies, subretinal fluid (SRF) resolution, and visual acuity (VA) were evaluated during a follow-up period of at least 4 months.
Results
Eighty-five eyes of 79 patients were analyzed, 36 eyes in group 1 and 49 in group 2. The treatment strategy at the first visit shifted from HD-PDT as the most performed treatment in group 1 to a more patient-tailored approach in group 2, with a wait-and-see policy in most cases. During follow-up, HD-PDT was performed significantly less in group 2 (89% vs. 45%; p < 0.001). At a mean follow-up time of 6.2 months, SRF resolved in 61% of the eyes in group 1 and in 55% in group 2 (p = 0.821). No difference in VA was observed between the groups at follow-up (p = 0.637).
Conclusion
During the shortage of verteporfin, a different treatment strategy was applied, with HD-PDT being performed less frequently. By implementing a more patient-tailored approach, the VA and the resolution rate of SRF remained similar to the year before the shortage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands, femke.vandentillaart@radboudumc.nl.
- Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
Zitieren
APA
van den Tillaart, F. M., Hartgers, F., Hoyng, C. B., & Yzer, S. (2024). Dealing with the Verteporfin Shortage: Treatment Options and Outcomes in Patients with Chronic and Non-Resolving Central Serous Chorioretinopathy. Ophthalmologica, 1-11. https://doi.org/10.1159/000542224
Vancouver
van den Tillaart FM, Hartgers F, Hoyng CB, Yzer S. Dealing with the Verteporfin Shortage: Treatment Options and Outcomes in Patients with Chronic and Non-Resolving Central Serous Chorioretinopathy. Ophthalmologica. 2024:1-11. doi:10.1159/000542224
BibTeX
@article{vandenTillaart2024,
author = {van den Tillaart, Femke M and Hartgers, Franca and Hoyng, Carel B and Yzer, Suzanne},
title = {Dealing with the Verteporfin Shortage: Treatment Options and Outcomes in Patients with Chronic and Non-Resolving Central Serous Chorioretinopathy},
journal = {Ophthalmologica},
year = {2024},
pages = {1--11},
doi = {10.1159/000542224}
}
EUVIMED